Sign in
4

Changes in Ownership

IRulya Therapeutics Inc. Filed Acc 0001415889-24-021869

CHIEF BUSINESS OFFICER AND COO bought 38,924 shares at an average $0.62 ($24,166)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hannah Brendan CHIEF BUSINESS OFFICER AND COO 2024-08-19 Purchase +2,155 $0.58 $1,250 259,771 D: show line 1 in the form
Hannah Brendan CHIEF BUSINESS OFFICER AND COO 2024-08-20 Purchase +2,500 $0.61 $1,525 262,271 D: show line 2 in the form
Hannah Brendan CHIEF BUSINESS OFFICER AND COO 2024-08-20 Purchase +3,424 $0.60 $2,054 265,695 D: show line 3 in the form
Hannah Brendan CHIEF BUSINESS OFFICER AND COO 2024-08-21 Purchase +2,280 $0.61 $1,391 267,975 D: show line 4 in the form
Hannah Brendan CHIEF BUSINESS OFFICER AND COO 2024-08-21 Purchase +5,000 $0.62 $3,100 272,975 D: show line 5 in the form
Hannah Brendan CHIEF BUSINESS OFFICER AND COO 2024-08-21 Purchase +23,565 $0.63 $14,846 296,540 D: show line 6 in the form
Open-market purchases · 38,924 sh · avg $0.62 · $24,166
Loading xslF345X05/form4-08212024_100803.xml…